Anthony Antoniou - The Royal Marsden
Anthony Antoniou - The Royal Marsden
Anthony Antoniou - The Royal Marsden
Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Colorectal cancer surgery<br />
and subsequent quality of<br />
life post resection<br />
Mr <strong>Anthony</strong> <strong>Antoniou</strong><br />
Senior Clinical Lecturer/ Honorary<br />
Consultant Colorectal Surgeon<br />
Upper and lower GI cancers - 16.07.2010
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
<strong>The</strong> surgical team<br />
Professor Lord Darzi, Professor of Surgery<br />
Mr Paris Tekkis, Reader in Surgery/ Honorary<br />
Consultant Surgeon<br />
Mr <strong>Anthony</strong> <strong>Antoniou</strong>, Senior Clinical Lecturer/<br />
Honorary Consultant Surgeon
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Trans Anal Endoscopic Microsurgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Indications for TEMs<br />
– Any benign rectal lesion above the dentate line<br />
within reach of the operating proctoscope<br />
– Selected T1 lesions<br />
– Selected T2 lesions with combined therapy
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Rectal cancer treatment options<br />
Local excision<br />
TME<br />
Disc excision of rectal wall<br />
Removal of all node bearing tissue<br />
Higher local recurrence rates<br />
Lower local recurrence rates<br />
Decreased operative morbidity<br />
Increased operative morbidity<br />
No functional disturbance<br />
Functional disturbance
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
TEM for benign disease<br />
Year Patients (N) Local<br />
Recurrence<br />
Rates (%)<br />
Menteges et al 1996 236 2<br />
Morshel et al 1998 226 3.6<br />
Nagy et al 1999 80 2.5<br />
Buess et al 2001 362 1.7<br />
Lloyd et al 2002 68 5.9<br />
Langer et l 2003 57 8.8<br />
Palma et al 2004 71 5<br />
Platell et al 2004 62 2.4<br />
Endreseth et al 2005 64 13<br />
Whitehouse et al 2006 146 4.8
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
TEM for T1 cancer<br />
Year Patient (N) Local Recurrence<br />
Rates (%)<br />
Buess et al 1988 12 0<br />
Buess et al 1992 25 4<br />
Winde et al 1996 24 4.2<br />
Smith et al 1996 30 10<br />
Langer et al 2001 16 12.5<br />
Demartines et al 2001 9 8.3<br />
Lee et al 2003 52 4.1<br />
Stipa et al 2006 23 8.6<br />
Floyd et al 2006 53 7.5<br />
Baatrup et al 2008 72 6
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
TEMs vs TME for T2 cancer<br />
• 70 patients with T2<br />
rectal cancer<br />
– 35 TEMs<br />
– 35 Laparoscopic<br />
resection<br />
• All received neoadjuvant<br />
treatment<br />
• Median follow up 84<br />
(72-96) months<br />
TEMs (%) TME (%)<br />
Local failure 5.7 2.8<br />
Distant<br />
metastases<br />
Local or<br />
Distant Failure<br />
2.8 2.8<br />
9 9<br />
Survival 94 94<br />
Lezoche et al Surg Endosc. 2008
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Recommended treatment plan
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Potential advantages of laparoscopic<br />
resection<br />
– Quicker return to<br />
function<br />
– Shorter stay<br />
– Decreased<br />
complications<br />
– Decreased pain
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Laparoscopic colon resection<br />
Positioning and ports
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Laparoscopic surgical resection
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Laparoscopy vs open surgery (colon cancer)<br />
Proven benefits<br />
– Quicker recovery from surgery<br />
– Lower wound infections<br />
– Lower respiratory problems<br />
– Huge benefit in elderly patient 40% less morbidity<br />
– Shorter length of Hospital Stay average 3-5 days<br />
– Quicker return to normal activity<br />
– Community nursing requirements 80%<br />
reduction<br />
– Lower hernia rates<br />
– Lower blood loss<br />
– Lower blood transfusion rate<br />
Conclusion of Trials<br />
N > 3000 patients
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Laparoscopic colorectal surgery<br />
Rectal cancer (survival RTC + CTs)<br />
Author Patients Follow-up Outcome<br />
Dulucq C<br />
Surg End 2005<br />
Morino M<br />
Surg Endo 2005<br />
Feliciotti F<br />
Surg Endo 2003<br />
Lezoche E<br />
Hepatogastro 2002<br />
Barlehner E<br />
Surg Endos 2005<br />
Delgado S, Lacy A<br />
Surg Endos 2004<br />
Poulin EC<br />
Surg Endos 2002<br />
218 5 years Same as open<br />
191 4 years Same as open<br />
124 4 years Same as open<br />
48 4 years Same as open<br />
194 4 years Same as open<br />
220
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Laparoscopy versus open surgery<br />
• Results the same as open surgery for colon cancer<br />
– Cancer survival<br />
– Lymph node harvest<br />
– Wound metastases<br />
– Anastomotic leak rate<br />
– Operative complication rate
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Ultra low anterior resection<br />
• 30% of cancers located in<br />
rectal area<br />
• patients with mid to low<br />
rectal cancers<br />
• sphincter preserving<br />
techniques<br />
– advent of stapling<br />
devices<br />
– improved surgical<br />
technique<br />
• acceptable oncological<br />
results and preserved<br />
sphincter function
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Ultra low anterior resection<br />
– increased rates of stool<br />
frequency, urgency, and<br />
incontinence due to the<br />
loss of the rectal reservoir<br />
– colonic reservoirs are<br />
superior in terms of<br />
functionality compared<br />
with SCAA at least within<br />
the first 2 years<br />
postoperatively
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Rectal cancer resections 2008 - 2010<br />
• Total 91 cases<br />
– 12 (13%) ultra low restoration of bowel continuity<br />
– 21 (23%) laparoscopic resection
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why choose <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
Early cancers<br />
– TEMs<br />
Colorectal carcinomas<br />
– traditional open<br />
– laparoscopic resections<br />
– ultra low resections and colo-anal anastamosis<br />
Synchronous colonic resections<br />
– HPB<br />
Recurrent cancer surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Presentation<br />
• within 2 years<br />
• depends on site<br />
• pain<br />
– perineum<br />
– buttock<br />
– leg<br />
• raised CEA<br />
• CT / MRI scan<br />
• colonoscopy
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Localised - perianastomotic
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Localised – connective tissue
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Localised – perineal recurrence
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Abdomino-perineal excision with sacrectomy
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Total pelvic exenteration with sacrectomy
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> – pelvic exenterations<br />
– 2006 - 2010<br />
– referrals - 96<br />
– n=58 (n=48 recurrent rectal cancer)<br />
– R0: 64%<br />
– R1: 16%<br />
– R2: 20%<br />
– sacrectomy: 40%<br />
– exenteration: 60%<br />
– EL: 35%<br />
– perineal flap: 35%<br />
– blood loss: 1500mls (250mls - 17l)
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Mortality and morbidity (n = 58)<br />
– any complications 50%<br />
– minor complications 57%<br />
– major complications 23%<br />
– intraoperative complications 9.1%<br />
– readmissions (90-day) 39%<br />
– Mortality 1.7%<br />
– length of stay (median; range) 14 days (3 – 86)
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
ICL – pelvic exenterations<br />
overall survival n=50 disease free survival n=40<br />
– overall survival – 46.8% 4 years<br />
– disease-free survival – 60% 4 years
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Years N= R0 Morbidity Mortality Survival<br />
Japan<br />
1983-2001 57 84% 58% 3.5% 23% 5yr<br />
Vienna 1987-2004 12 -- 42% 0% 17% 3yr<br />
Dutch 1994-1999 37 52% 82% 0% 41% 3yr<br />
Denver 1983- 45 73% 56% 4% 31% 5y<br />
Mayo 1990-1994 16 87% 50% 0% 48% 2y<br />
MSK 1987-2004 29 62% 59% 3% 47% 5yr<br />
Leeds<br />
(ASR) 1996-2006 40 62% 48% 2.5% 44% 3yr<br />
Imperial 2006-2010 58 65% 50% 1.7% 47% 4yr
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Multi-disciplinary team approach<br />
• oncologist / radiotherapist<br />
• surgeons:<br />
– colorectal, plastic, orthopaedic, urology,<br />
gynaecology<br />
• radiologist: diagnostic, interventional<br />
• anaesthetist: pain specialist, intensivist<br />
• nurses: stoma, nutrition, tissue viability<br />
• physiotherapy<br />
• pathologist
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Quality of life following<br />
colorectal surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Quality of life following colorectal surgery<br />
Factors evaluated<br />
– bowel function<br />
– urinary function<br />
– sexual function<br />
– need for stoma<br />
Cornish et al. Ann Surg Oncol. 2007 Jul;14(7):2056-68
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
QoL APER vs AR<br />
– Avoiding a permanent stoma following rectal cancer<br />
excision is believed to improve quality of life (QoL)<br />
– meta-analysis of studies published between 1966<br />
and 2006<br />
– Quality of life outcomes measured by EORTC QLQ<br />
C30, CR38 and SF-36 for APER vs AR<br />
– outcomes for 1,443 patients from 11 studies, of<br />
whom 486 (33%) underwent APER<br />
– QoL assessments were made at periods of up to 2<br />
years following surgery
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
No Diff.<br />
AR<br />
AR<br />
APER
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Sexual and urinary outcomes after rectal<br />
cancer excision<br />
• assessment<br />
– at pre-op, 4mths, 8mths, then yearly for up to 5<br />
yr<br />
• Primary end points in sexual function<br />
– sexual activity<br />
– frequency of sexual intercourse per month<br />
– ability to achieve arousal<br />
– ability to attain orgasm<br />
– presence of dyspareunia<br />
Tekkis et al. Dis Colon Rectum. 2009 Jan;52(1):46-54
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Sexual and urinary outcomes after rectal<br />
cancer excision<br />
• Primary end points in urinary function<br />
– urinary urgency<br />
– urinary incontinence<br />
– nocturia<br />
– poor urinary stream<br />
– straining to pass urine<br />
– urinary retention<br />
– use of urinary catheter
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Study population<br />
AR APR p<br />
value (n=222) (n=73)<br />
mean age (yrs) 59.3 65.5 0.001<br />
median follow up (yrs) 3.28 2.95 NS<br />
radiotherapy 33.8% 60.3%
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Summary – sexual function<br />
• APR<br />
– less sexually active<br />
– intercourse<br />
– dyspareunia<br />
• radiotherapy dyspareunia<br />
• age ≥ 65 years sexual dysfunction across ALL<br />
domains
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Summary – urinary function<br />
• APR<br />
– urinary urgency<br />
– urinary incontinence<br />
– poor stream<br />
– urinary retention
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Conclusion<br />
– no differences in general QoL following APER vs AR<br />
– sexual and urinary outcomes should be considered<br />
when planning operative management<br />
– appropriate patient selection<br />
– individualization of care
<strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong> Upper and lower GI cancers - 16.07.2010<br />
Why <strong>The</strong> <strong>Royal</strong> <strong>Marsden</strong><br />
We have<br />
• Word leading Oncology Department<br />
• Surgical expertise<br />
– Trans- anal surgery<br />
– Laparoscopic surgery<br />
– Low rectal cancer surgery<br />
– Synchronous liver/ colorectal surgery<br />
– Recurrent cancer surgery<br />
• Excellence in endoscopy<br />
• Imaging resources<br />
• Nurse practitioner<br />
• Dedicated junior staff